To include your compound in the COVID-19 Resource Center, submit it here.

Favrille: Third strike at B cell lymphoma

Although personalized therapy has shown promise in indications such as B cell lymphoma, bringing it to patients is a challenge, because creation of the vaccine is a slow process. Favrille Inc. believes its manufacturing technology - based on insect cell cultures - can solve the problems of speed and efficiency that exist with other methods.

Individualized vaccines are derived through identification from tumor biopsies of genes encoding patient-specific idiotypic tumor proteins. Larger

Read the full 722 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE